Chapter 13. The Impact of Genomics on Antimicrobial Drug Discovery and Toxicology CBBL - Young-sik Sohn-

Slides:



Advertisements
Similar presentations
Analysis of High-Throughput Screening Data C371 Fall 2004.
Advertisements

RNA INTERFERENCE RNAI RELATION TO P53 USING RNAI TO SILENCE MUTANT P53 IN BLADDER CANCER CELLS & SIRNA BAR CODE SCREENING By: Chelsey Maag.
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
Identification of Novel Virulence-Associated Genes via Genome Analysis of Hypothetical Genes Sara Garbom, Åke Forsberg, Hans Wolf- Watz, and Britt-Marie.
Proteomics and “Orphan” Receptors Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
Goals of PATHOGENOMICS related research Chief Scientist Office Ministry of Health Israel.
Dairian Wan | Bioinformatics © 2003, Genentech 1 6/1/2015 Bioinformatics Overview 8 November 2004 Dairian Wan.
S TRUCTURAL B IOINFORMATICS. A subset of Bioinformatics concerned with the of biological structures - proteins, DNA, RNA, ligands etc. It is the first.
2 March, 2005 Chapter 12 Mutational dissection Normal gene Altered gene with altered phenotype mutagenesis.
Bio 465 Summary. Overview Conserved DNA Conserved DNA Drug Targets, TreeSAAP Drug Targets, TreeSAAP Next Generation Sequencing Next Generation Sequencing.
Biol518 Lecture 2 HTS and Antibiotic Drug Discovery.
Bacterial Physiology (Micr430)
What Do Toxicologists Do?
Discussion Our current results suggest that it is possible to identify susceptibility regions using this methodology. The presented method takes advantage.
OMICS Group Contact us at: OMICS Group International through its Open Access Initiative is committed to make genuine and.
Review of important points from the NCBI lectures. –Example slides Review the two types of microarray platforms. –Spotted arrays –Affymetrix Specific examples.
Food Safety Assessment Kevin Greenlees, PhD, DABT Kathleen Jones, PhD.
Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.
Research & Innovation Horizon societal challenge 1 Open Info Day Funding Opportunities for SMEs Horizon 2020 "Health, demographic change and wellbeing"
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
Systematic Analysis of Interactome: A New Trend in Bioinformatics KOCSEA Technical Symposium 2010 Young-Rae Cho, Ph.D. Assistant Professor Department of.
Paola CASTAGNOLI Maria FOTI Microarrays. Applicazioni nella genomica funzionale e nel genotyping DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE.
Risk assessment: Bt corn MON810 Risk assessment: identifying and evaluating possible dangers predicting the chances the danger will occur assessing the.
Integrating Scientific Advances into Regulation: Pharmacogenomics and Pharmacogenetics Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research.
Knowledgebase Creation & Systems Biology: A new prospect in discovery informatics S.Shriram, Siri Technologies (Cytogenomics), Bangalore S.Shriram, Siri.
Asia’s Largest Global Software & Services Company Genomes to Drugs: A Bioinformatics Perspective Sharmila Mande Bioinformatics Division Advanced Technology.
A new antivirulence approach against pathogenic bacteria A new antivirulence approach against pathogenic bacteria May 2005 Sonia Escaich - President &
Mapping protein-DNA interactions by ChIP-seq Zsolt Szilagyi Institute of Biomedicine.
Biol518 Lecture 2 HTS and Antibiotic Drug Discovery.
A systems biology approach to the identification and analysis of transcriptional regulatory networks in osteocytes Angela K. Dean, Stephen E. Harris, Jianhua.
Does gene order matter? Cis-regulatory elements, proteins, and messengers are integrated into biological circuits. Does gene location in the genome affect.
Beyond the Human Genome Project Future goals and projects based on findings from the HGP.
Gene expression and DNA microarrays Old methods. New methods based on genome sequence. –DNA Microarrays Reading assignment - handout –Chapter ,
TOPICS IN (NANO) BIOTECHNOLOGY
Fig Chapter 12: Genomics. Genomics: the study of whole-genome structure, organization, and function Structural genomics: the physical genome; whole.
A New Oklahoma Bioinformatics Company. Microarray and Bioinformatics.
Finish up array applications Move on to proteomics Protein microarrays.
Bioinformatics Brad Windle Ph# Web Site:
Global network analysis of drug tolerance, mode of action and virulence in methicillin-resistant S. aureus Chloe Jones Loyola Marymount University BIOL368:
Reconstruction of Transcriptional Regulatory Networks
Function first: a powerful approach to post-genomic drug discovery Stephen F. Betz, Susan M. Baxter and Jacquelyn S. Fetrow GeneFormatics Presented by.
Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.
Screening Methods Lecture – 4 Tahir. Early screening strategies tends to be empirical, labour intensive and low success rates. As the no of commercially.
Samudrala group - overall research areas CASP6 prediction for T Å C α RMSD for all 70 residues CASP6 prediction for T Å C α RMSD for all.
Systems Biology ___ Toward System-level Understanding of Biological Systems Hou-Haifeng.
Bioinformatics MEDC601 Lecture by Brad Windle Ph# Office: Massey Cancer Center, Goodwin Labs Room 319 Web site for lecture:
TOXICOGENOMICS.
While gene expression data is widely available describing mRNA levels in different cancer cells lines, the molecular regulatory mechanisms responsible.
Bioinformatics and Computational Biology
ANALYSIS OF GENE EXPRESSION DATA. Gene expression data is a high-throughput data type (like DNA and protein sequences) that requires bioinformatic pattern.
Discovering Modes of Action for Therapeutic Compounds Using a Genome-Wide Screen of Yeast Heterozygotes Pek Yee Lum, Christopher D. Armour, Daniel D. Shoemaker,
Inflammatory Bowel Diseases November 19, 2007 NCDD Meeting Chair: Daniel K. Podolsky, MD Vice Chair: Eugene B. Chang, MD.
Other uses of DNA microarrays
Genome sequencing of disease causing microorganism Romana Siddique.
Different microarray applications Rita Holdhus Introduction to microarrays September 2010 microarray.no Aim of lecture: To get some basic knowledge about.
Shows tendency for mergers. These big companies may be shrinking – much research is now outsourced to low cost countries like Latvia, India, China and.
Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery & Therapeutics Services > Generation of Stable Cell Lines.
신기술 접목에 의한 신약개발의 발전전망과 전략 LGCI 생명과학 기술원. Confidential LGCI Life Science R&D 새 시대 – Post Genomic Era Genome count ‘The genomes of various species including.
Molecular Modeling in Drug Discovery: an Overview
BIOBASE Training TRANSFAC ® Containing data on eukaryotic transcription factors, their experimentally-proven binding sites, and regulated genes ExPlain™
Page 1 Computer-aided Drug Design —Profacgen. Page 2 The most fundamental goal in the drug design process is to determine whether a given compound will.
Single Nucleotide Polymorphisms (SNPs
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
An Introduction to Medicinal Chemistry 3/e
A new antivirulence approach against pathogenic bacteria
VWF sequence variants: innocent until proven guilty
Benjamin Wooden, Nicolas Goossens, Yujin Hoshida, Scott L. Friedman 
Angela L. Rasmussen, Michael G. Katze  Cell Host & Microbe 
Three major barriers to the integration of metagenomics into pharmacology and toxicology. Three major barriers to the integration of metagenomics into.
Discussion and Future Work
Presentation transcript:

Chapter 13. The Impact of Genomics on Antimicrobial Drug Discovery and Toxicology CBBL - Young-sik Sohn-

Introduction  Genome-scale DNA sequence information offers potential molecular targets  Newly developed genomic technologies promise to impact all facets of the drug discovery

Target-based drug discovery

Challenges of New Drug Discovery  Need for new antibiotic discovery A mechanism that contributes to antibiotic resistance is drug exclusion by efflux systems

Challenges of New Drug Discovery  Desirable properties of antimicrobial targets Antimicrobial targets should meet the criteria of spectrum, selectivity, functionality, and essentiality ① provide adequate spectrum and selectivity ② essential for growth or viability of the pathogen ③ knowledge on the function is necessary in order to design assays and high-throughput screens

 Mining genomes for antimicrobial drug targets Microbial Genomics and Drug Target Selection

 Comparative genomics: target spectrum and selectivity Useful approach to estimate target spectrum and selectivity Offer the opportunity to develop broad-spectrum antibiotics Significant proportion of genomes encode proteins with no known function Microbial Genomics and Drug Target Selection

 Genetic strategies: verifying the essentiality or expression of gene targets Combine molecular biology and common drug screening ↓ expediting the identification of antimicrobials with unique modes of action ① signature-tagged mutagenesis (STM) ② in vivo expression technology (IVET) ③ differential fluorescence induction (DFI) Microbial Genomics and Drug Target Selection

 Microarray analysis: establishing function for new targets Identification of new regulatory pathways or networks ↓ design novel drugs Screen populations of clinical isolates or related strains (Used as a comparative genomics tool) ↓ conserved genes/genetic variation Microbial Genomics and Drug Target Selection

Determining Therapeutic Utility: Drug Target Screening and Validation  Target-based drug screening Strain array for antibacterial discovery ○ any target ○ the molecular target can be confirmed with a functional assay ○ identify several compounds with good inhibitory activity ○ Strains be screened at any time and at low cost

Determining Therapeutic Utility: Drug Target Screening and Validation  Target-based drug screening In silico screening and structure-based drug design

Determining Therapeutic Utility: Drug Target Screening and Validation  Target-based drug screening Surrogate-ligand-based screening ○ Surrogate ligand: short peptides bind to functional sites of target proteins inhibiting target’s function ○ Important aspect: data of protein activity isn’t required identify active site of unknown function

Determining Therapeutic Utility: Drug Target Screening and Validation  Microarrays and drug target validation Microarray analysis of inhibition of gene function ○ establish whether a putative target is required to generate the drug signature ○ Microarray analysis of inhibition may be useful for validation (a compound often may affect unintended components)

Using microarray-based gene expression profiling to identify an unknown toxicant’s mechanism of action

Genomics and Toxicology: The Emergence of Toxicogenomics  Microarrays in mechanistic toxicology ToxBlot arrays: investigating toxicity processes ≒ 600 marker genes for array construction genes for toxicology  Goal of toxicogenomics Identify groups of genes that are tightly correlated with known classes of toxicants

Genomics and Toxicology: The Emergence of Toxicogenomics  Microarrays in predictive toxicology Goal : predict adverse drug reduce the time reduce expense

Summary  Therapeutic inhibition will be done by target-based strategies which combine computational and experimental approaches  Microarray-based gene expression profiling is becoming a standard in mechanistic toxicology and is providing important insights into the mechanisms of action  Toxicogenomics is expected to impact the safety assessment of new drugs and to reduce the number of drug failures

Thank you for your attention